MARKET

IKT

IKT

Inhibikase Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.56
-0.14
-2.09%
Closed 16:08 01/26 EST
OPEN
6.86
PREV CLOSE
6.70
HIGH
6.86
LOW
6.54
VOLUME
85.12K
TURNOVER
--
52 WEEK HIGH
11.80
52 WEEK LOW
6.40
MARKET CAP
63.04M
P/E (TTM)
-13.5397
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Week Ahead In Biotech: FDA To Issue Decisions On Merck And Aurinia Drug Applications
Biotech stocks advanced in the week ended Jan. 15, defying the softness experienced by the broader market. Pre-announcements continued to pour in, with most companies suggesting better-than-forecast revenues.
Benzinga · 01/16 18:20
Inhibikase Therapeutics Announces Partnership With Clintrex Research Corporation; C. Warren Olanow, MD, To Serve As Interim Chief Medical Officer
ATLANTA, Jan. 4, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related
Benzinga · 01/04 13:10
Inhibikase Therapeutics Announces Partnership with Clintrex Research Corporation; C. Warren Olanow, MD, to Serve as Interim Chief Medical Officer
, /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders, announced today that it has formed a partnership with Clintrex Resea...
PR Newswire - PRF · 01/04 13:01
Inhibikase Therapeutics Announces Partnership with Clintrex Research Corporation; C. Warren Olanow, MD, to Serve as Interim Chief Medical Officer
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders, announced today that it has formed a partnership with Clintrex Research Corporation (CL...
PR Newswire · 01/04 13:01
The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 29)
Benzinga · 12/30/2020 13:08
Tenax Therapeutics, Regional Health Properties leads healthcare gainers; Arcturus Therapeutics, Actinium Pharmaceuticals among major losers
Gainers: Tenax Therapeutics (TENX) +132%, Regional Health Properties (RHE) +38%, IRIDEX (IRIX) +22%, INmune Bio (INMB) +17%, Mirum Pharmaceuticals (MIRM) +8%.Losers: Arcturus Therapeutics (ARCT) -53%, Actinium Pharmaceuticals (ATNM) -24%, Alpine Immune Sciences (ALPN) -17%, Inhibikase Therapeutics (IKT) -16%, Seelos Therapeutics (SEEL)
Seekingalpha · 12/29/2020 16:03
The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28)
Benzinga · 12/29/2020 13:09
Inhibikase Therapeutics Announces Closing of Initial Public Offering
, /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase"), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders that arise inside and outside of the brain, announced today the clo...
PR Newswire - PRF · 12/28/2020 15:33
More
Forecast
EPSBVPSCFPS
No Data
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IKT. Analyze the recent business situations of Inhibikase Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
About IKT
Inhibikase Therapeutics Inc. is a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The Company’s lead product candidate, IkT-148009 is for the treatment of PD, and for the treatment of gastrointestinal (GI), complications that arise as early symptoms of PD in patients. The Company’s kT-148009, is a brain penetrant c-Abl protein kinase inhibitor that halts disease progression and reverses functional loss in the brain and reverses neurological dysfunction in the GI tract. The Company’s products candidate also include IKT-001Pro, which is a prodrug of the anticancer agent Imatinib, and used as a treatment for stable-phase chronic myelogenous leukemia (CML), and IKT-01427 for progressive multifocal leukoencephalopathy (PML).

Webull offers kinds of Inhibikase Therapeutics Inc stock information, including NASDAQ:IKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IKT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IKT stock methods without spending real money on the virtual paper trading platform.